Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to ...

Pleural empyema is an infectious disease of the pleural space that accompanies bacterial pneumonia 1. Tuberculous empyema develops due to the rupture of pulmonary lesions or the dissemination of ...

Video-assisted thoracic surgery decortication for phase 3 thoracic empyema is widely accepted, but its optimal timing has not been established. We aim to investigate and assess this timing, in terms ...

Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to ...

DENVER – Patients with early stage malignant pleural mesothelioma (MPM), a cancer that develops in the lining of the lungs, may be eligible for aggressive multi-modality therapy involving surgery, ...

The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding ...

Sugarbaker DJ, Bueno R, Krasna MJ, Mentzer SJ, Zellos L (eds). Adult Chest Surgery. New York: The McGraw-Hill Company, 2009. Sugarbaker DJ, Norberto JJ, Swanson SJ. Surgical staging and work-up of ...

Multiomics profiling for prediction of immunotherapy response in advanced pleural mesothelioma: Sub-study of the NIPU trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

The research, published this month in The Annals of Thoracic Surgery, offers a modern, data-driven counterpoint to the widely debated Mesothelioma and Radical Surgery 2 (MARS2) trial, which raised ...

(Singapore, September 11, 2023, 10:05 a.m. SGT) – Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events ...

Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial. This is an ASCO Meeting Abstract from the ...